Effects of thrombolysis for acute stroke in patients with pre-existing disability

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 3, 2003, Pages 193-197

  Foell, R Blaine Taylor ^a,e   Silver, Brian ^b   Merino, Jose G ^c   Wong, Edward H ^a   Demaerschalk, Bart M ^d   Poncha, Fali ^a   Tamayo, Arturo ^a   Hachinski, Vladimir ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d MAYO CLINIC   (United States)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; COMORBIDITY; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DRUG EFFECT; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NEUROLOGIC DISEASE; STROKE; SURVIVAL; SYMPTOMATOLOGY; TREATMENT PLANNING;

EID: 0041426517     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA stroke trial. Stroke 1997;28:2119-25.
3. Hill MD, Buchan AM. Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES investigators. Can J Neurol Sci 2001;28:232-8.
4. von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello S, Manelfe C, et al. Acute stroke: usefulness of early findings before thrombolytic therapy. Neuroradiology 1997;205:327-33.
5. Hacke W, Kaste M, Fieschi C, von Kummar R, Davalos A, Meier D, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998;352:1245-51.
6. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. JAMA 1999;282:2019-26.
7. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
8. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-70.
9. Wolfe CDA, Taub NA, Woodrow EJ, Burney PGJ. Assessment of scales of disability and handicap for stroke patients. Stroke 1991;22:1242-4.
10. Anderson C. Baseline measures and outcome predictions. Neuroepidemiology 1994;13:283-9.
11. Harwood RH, Gompertz P, Pound P, Ebrahim S. Determinants of handicap 1 and 3 years after a stroke. Disabil Rehabil 1997;19:205-11.
12. Bamford J, Dennis M, Sandercock P, Burn J, Warlow C. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry 1990;53:824-9.
13. Silver B, Demaerschalk B, Merino JG, Wong E, Tamayo A, Devasenapathy A, et al. Improved outcomes in stroke thrombolysis with pre-specified imaging criteria. Can J Neurol Sci 2001;28:113-9.
14. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-60.
15. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-18.